Pre-made Enokizumab benchmark antibody ( Whole mAb, anti-IL9 therapeutic antibody, Anti-HP40/IL-9/P40 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Enokizumab biosimilar, Whole mAb, Anti-IL9 Antibody: Anti-HP40/IL-9/P40 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enokizumab, also known as MEDI-528, is a humanized IgG1κ type monoclonal antibody direct against the cytokine interleukin-9 (IL-9). This drug was developed by MedImmune and has been investigated in the treatment for asthma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-185-1mg	1mg	3090
GMP-Bios-ab-185-10mg	10mg	Inquiry
GMP-Bios-ab-185-100mg	100mg	Inquiry
GMP-Bios-ab-185-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Enokizumab biosimilar, Whole mAb, Anti-IL9 Antibody: Anti-HP40/IL-9/P40 therapeutic antibody
INN Name	Enokizumab
Target	IL9
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Asthma
Development Tech	na